Eylea HD injected every 12 or 16 weeks controls neovascular age-related macular degeneration to a similar extent as Eylea ...

In July 2025, 3 4DMT announced its intent to accelerate its 4D-150 4FRONT phase 3 program in wet AMD and lay off approximately 25% of staff. 4DMT noted that this transition supported the company’s ...

Enrollment for 4FRONT-1, the first registrational trial for 4D-150 in wet AMD, was completed within an approximately 11-month period, ahead of ...

A new study published in Clinical & Experimental Ophthalmology found that faricimab was effective in treating patients with neovascular age-related macular degeneration (nAMD) who had not previously ...

D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, and the 4DMT logo are trademarks of 4DMT. All of the Company’s product candidates are in clinical or preclinical development and have ...

Ocular Therapeutix's current wet AMD treatment is dominated by anti-VEGF drugs, with EYLEA holding a 63% global market share in 2024. Read why OCUL stock is a sell.

Detailed price information for Ocular Therapeut (OCUL-Q) from The Globe and Mail including charting and trades.

Dr Peter Bloomfield, director of research at the Macular Society, reflects on research developments and the meaningful ...

Breye is advancing danegaptide to Phase II trials after the drug showed signs of improving disease activity in a Phase Ib ...

Long-term faricimab treatment for DME provides sustained efficacy and a safety profile consistent with phase 3 trials for at least 4 years, study shows.

New Dupixent ® (dupilumab) data highlight its clinical and real-world impact across dermatological, respiratory and gastrointestinal diseases, including analyses of food allergy sensitization in ...

Regeneron-invented therapies, including first-time Phase 3 presentations for two distinct investigational allergen-blocking antibodies for cat and birch allergies ...